by Raynovich Rod | Feb 19, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update...
by Raynovich Rod | Jan 29, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Solid earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous...
by Raynovich Rod | Jan 19, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical...
by Raynovich Rod | Jan 14, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Update 1/15 Fibrocell Science has moved another 3.5% probably related to recent moves of Intrexon (XON) up 3% today. Both FCSC and XON have Third Security LLC as major holder, PACB is down 4.78% on profit taking. Biotech is a tad weak today after 3 days of the...
by Raynovich Rod | Jan 12, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy test Continuous monitoring of tumor specific information and molecular...
by Raynovich Rod | Jan 7, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Up For the Year Biotech stocks resumed their upward move near all time highs in FBT and XBI.We will review many of the stocks in our portfolios at the JPMorgan Conference next week. Motif Summary Rayno Large Cap Biopharma up 36.4% over one year...
by Raynovich Rod | Jan 7, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were two...
by Raynovich Rod | Jan 1, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios:...
by Raynovich Rod | Dec 29, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Many Big Winners Are Among Rayno Diagnostics and Tools Stocks in 2014 Abaxis (ABAX) up 46% A major “Point of Care” (POC) Dx Player in veterinary and human markets. Exact Sciences (EXAS) up 135% An emerging Dx player with non-invasive, DNA based test for...
by Raynovich Rod | Nov 26, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD....
